ResearcherSorbonne UniversitéNo recent work listed

Paul McLellan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-7494-979X; OpenAlex author ID A5043038701. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 paper

Papers 1

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Déwi Vernerey · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Daniel Pietrasz · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Solène Doat · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Isabelle Trouilloud · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Christophe Louvet · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Pascal R. Hammel · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗
Jean‐Baptiste Bachet · 1 shared paper, 2021 · strength 0.12
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.